Ki-67 and Presence of Liver Metastases Predicts Progression in Pancreatic Neuroendocrine Neoplasms (pNENs) Abstract #2033

Introduction: In pancreatic neuroendocrine neoplasms (pNENs), size ≤20 mm and Ki-67 ≤2% suggest indolent behavior, but no factor alone can predict prognosis.
Aim(s): To explore prognostic factors better predicting pNENs prognosis
Materials and methods: We investigated factors predictive of tumor progression in 80 pNENs surgically resected from 1995 to 2015 in a single Institution.
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Massimo Milione

To read results and conclusion, please login ...

Further abstracts you may be interested in

#9 Case Management of Metastatic carcinoid of the Foregut,Midgut and Hindgut:the relevance of Ki-67 prognostication
Introduction: The predictive value of tumor grade in the prognosis of carcinoid is insufficient and somehow misleading. The grade and differentiation in carcinoid tumors must be seen in conjunction with the Ki-67 index. The Ki-67 protein is a cellular marker for proliferation, present during all active phases of the cell cycle (G1, S, G2 and mitosis) and absent from resting cells (G0). It is therefore an excellent marker to determine the growth fraction of a given cell population. The Ki-67 labelling index is often correlated with the clinical course of carcinoid.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Marianne J Kohler
#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#25 Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis
Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Mazen Hassanain
#30 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
Introduction: Normal adult lungs contain scattered pulmonary neuroendocrine cells (PNEC). Reactive PNEC hyperplasia is commonly observed in persons who live at high altitude, in cigarette smokers, and in numerous lung diseases. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) is a rare entity in which PNEC hyperplasia appears without predisposing conditions. According to the 1999 WHO lung tumor classification, DIPNECH is thought to be primarily a neuroendocrine proliferative process, which can be associated with carcinoid tumors and with a clinical picture of constrictive obliterative bronchiolitis. To date, available data regarding the treatment and the prognosis of this rare condition is limited.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simona Grozinsky-Glasberg
#80 Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy
Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team